Locations:
SearchA Cleveland Clinic oncologist has a few ideas
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dale Shepard, MD, PhD
Web entrepreneur and philanthropist Sean Parker’s recent $250 million donation to fund collaborative cancer immunotherapy research is meant to accelerate progress in this promising field.
Cleveland Clinic Cancer Center oncologist Dale Shepard, MD, PhD, has some suggestions for how to spend this windfall. In this guest commentary for Everyday Health, Dr. Shepard, who directs the Cancer Center’s phase 1 clinical trials and sarcoma programs, recommends three steps to maximize the effectiveness of Parker’s gift.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust